enGenome, a bioinformatics company developing software solutions for the diagnosis of genetic diseases has been selected as one of 65 European startups and SMEs for the first European Innovation Council (EIC) Accelerator call of 2021 and will benefit from a grant of € 1.7 million plus the opportunity to receive an investment from the European Commission.
Previously known as SME Instrument, the EIC Accelerator is a new European financial instrument that supports the growth process of highly innovative companies and start-ups through grants and investments in equity. EIC has a budget of approximately € 1.1 billion for 2021.
The eVai software, developed by enGenome to support doctors in the diagnosis of rare genetic diseases through the interpretation of genomic variants, has overcome a highly competitive selection process to win the approval of the European Innovation Council. Such selection consisted of two phases in which applications were evaluated by external experts and interviewed in front of a jury of investors and entrepreneurs. The success rate for this first call was less than 3%.
Ettore Rizzo, CEO and co-founder of enGenome considers this recognition much more than just an important financial injection: